Scientists hunt for clues to breast cancer treatment resistance in 10 patients
NCT ID NCT06518382
First seen Apr 16, 2026 · Last updated May 05, 2026 · Updated 3 times
Summary
This study examines tumor samples from 10 HER2-positive breast cancer patients who still had cancer after standard chemotherapy and trastuzumab. Researchers compare tissue taken before and after treatment to understand how the tumor and its surroundings change to resist therapy. The goal is to find new markers that could lead to better treatments, but no new drugs are being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS San Raffaele Hospital
RECRUITINGMilan, Lombardy, 20132, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.